Navigation Links
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
Date:1/28/2011

hase, during which all patients were titrated to their individually optimal tapentadol ER dose (100–250 mg two times per day), followed by a 12-week, double-blind maintenance phase, during which patients were randomized either to continue taking tapentadol ER (at their optimal dose) or to receive placebo.

The primary efficacy endpoint of the study was to measure the change in average pain intensity, as determined by a twice-daily, 11-point pain rating scale or numerical rating scale (NRS; 0='no pain,' 10='pain as bad as you can imagine'), from the point of randomization.  Safety was also assessed throughout the study.

At the start of the 3-week, open-label phase, the majority of patients (79.4%) reported severe pain (greater than or equal to 6 on the 11-point NRS) with a mean pain intensity of 7.3. By the end of the open-label phase, the mean pain intensity was reduced to 3.5. Following randomization, over the double-blind treatment phase to week 12, pain increased in the placebo group (as demonstrated by the average change in pain intensity of 1.4), while in the tapentadol ER group, pain relief was maintained, as indicated by the change in pain intensity value of 0.0. The mean difference between the tapentadol ER and placebo groups in the change in average pain intensity was -1.3 on the 11-point NRS (95 percent CI; p<0.001, tapentadol ER vs. placebo).  Researchers observed statistically significant differences in favor of tapentadol ER using all imputation methods.

In a secondary analysis, where rates of those who responded to treatment were calculated, 53.6 percent of patients receiving tapentadol ER and 42.2 percent of patients receiving placebo (p=0.017) experienced at least a 30 percent improvement in pain intensity measured from pre-titration to week 12 of the double-blind treatment period.

The patient's global impression of change (PGIC) provided an additional secondary analysis where patients evaluated on a 7-
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
3. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
4. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
6. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
7. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
8. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
9. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
10. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
11. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Pharmaceutical Research and Manufacturers of ... last year in the research and development (R&D) of ... majority of all biopharmaceutical R&D spending – both public ... . The new R&D numbers, the result of ... in the newly released PhRMA 2015 Biopharmaceutical ...
(Date:4/20/2015)... April 20, 2015 Stand Up To Cancer (SU2C) and ... $20 million Dream Team to attack the number one cancer ... Meeting of the American Association for Cancer Research (AACR), Scientific ... people in the United States will ... 158,040 will die from it, making lung cancer the leading ...
(Date:4/20/2015)... PALO ALTO, Calif. , April 20, 2015 ... study demonstrate positive trends in the ability of ... slow the progression of amyotrophic lateral sclerosis (ALS, ... over a 6-month treatment period. While NP001,s slowing ... of the study was not statistically significant, clinically ...
Breaking Medicine Technology:PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... N.Y., March 2, 2011 Lixte ... that the company has received a $244,479.25 grant ... awarded to further development and commercialization of Lixte,s novel anti-cancer ... the Patient Protection and Affordable Care Act of 2010 to ...
... 2011 InspireMD , developer ... has expanded its MGuard production facilities to meet the ... accelerating demand for MGuard include the recent recommendation of ... be considered for PCI of highly thrombotic or SVG ...
Cached Medicine Technology:Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government 2InspireMD Boosts MGuard Production Capacity 2
(Date:4/20/2015)... California (PRWEB) April 20, 2015 At ... Entertainment held the “RockNRolla Movie Awards” EcoLuxe Lounge, with ... Los Angeles’ leading producer of sustainable product placement in ... providers of socially conscious and ecologically sound goods and ... film star Chase Masterson hosted the Choices Celebrity Interview ...
(Date:4/20/2015)... 2015 Goodreads is sponsoring a book ... It’s Good for You and Your Company between Mar. ... and Rick Lindquist have released a new book ... Good for You and Your Company. The book discusses ... woes - employer-funded individual health insurance. , According ...
(Date:4/20/2015)... Early registration is open for the ... space at the start line. Returning to James Kealoha ... limited to 500 participants (actually there’s only 499 spots since ... , Now thru April 30, the entry fee is only ... May 1st, the fee goes up to $200 and $100, ...
(Date:4/20/2015)... TROY Healthcare Solutions will be hosting an ... which provides the ultimate level of security for prescriptions, ... Anthem Suite Hotel in the Socrates Room, located at ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief 15-20 minute presentations each hour ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 "It's so ... done for our family. Initially, I really thought I ... it would end. But what I've discovered is this ... to be together, support each other and walk through ... Keller. "I have learned way more from these families ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 2Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 3
... What: Sacramento - On Tuesday, April 28, at 1:30 p.m., Donate, ... press conference to announce, Padilla,s ... grade health classes to include 15 minutes of education regarding, ... bill ultimately, would provide California ...
... total $36.1 million, an increase of 22% over 2007- ... for the fourth quarter, $14.4 million for the full ... (Nasdaq: ENCO ), a full service ... and management capabilities for clinical trials and patient registries ...
... Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, ... on its corporate activities. , One of the ... previous financial disclosures, is the conclusion of a ... Complex (MCC), formulated as Urocidin(TM), for the intravesical ...
... Smoke-Free Restaurants, Bars and Workplaces StatewideAUSTIN, Texas, April ... committee prepares to consider comprehensive smoke-free workplace legislation ... is launching a radio advertising campaign urging the ... all Texans from harmful secondhand smoke.(Logo: ...
... Colo., April 27 Heska Corporation (Nasdaq: HSKA ... Heska Corporation Invites You to Listen to Its ... May 5, @ 9:00 a.m. (MDT)Where: www.heska.com ... on the front page of this website)How: ...
... a complimentary resource that can assist in planning for, controlling and ... ... TX (PRWEB) April 27, 2009 -- With more than 100 deaths ... swine influenza outbreak has triggered global concern as governments everywhere scramble ...
Cached Medicine News:Health News:Donate Life California to Hold Press Conference on Organ Donation Education, April 28, 1:30 p.m., on State Capitol West Steps 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Bioniche Provides a Corporate Update 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 3
... The SmartPulse 10.6 CO2 system was expressly ... in cosmetic surgery. A special source and ... it possible to create particular high energy ... impulses (technically known as 'top-flat shaped') allow ...
... laser is the ideal instrument for safe, ... Plus, the majority of surface lesions can ... range of scar tissue, with a minimum ... with the elimination of anaesthetics, risks and ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... and efficient method applied to dermatological therapy ... research and development with hundreds of users, ... source, but rather a platform for future ... in pulsed-light-based technology, the most valid and ...
Medicine Products: